Pittaway K M, Rodriguez R E, Hughes J, Hill R G
Parke-Davis Research Unit, New Addenbrookes Hospital, Cambridge, U.K.
Neuropeptides. 1987 Jul;10(1):87-108. doi: 10.1016/0143-4179(87)90092-8.
The C-terminal octapeptide of cholecystokinin (CCK 8) was administered intrathecally to rats. Doses in the nanogram range produced weak but significant antinociception in the paw pressure test five minutes after injection whereas microgram doses of CCK 8 produced hyperalgesia. The CCK 8-induced analgesia or hyperalgesia was not seen in the tail flick test and was not associated with motor incapacitation or any other noticeable side effects. The C-terminal tetrapeptide of CCK (CCK 4) and pentagastrin were found to be ineffective in all tests but caerulein and molluscan cardioexcitatory neuropeptide (FMRF-amide), like CCK 8, produced antinociception in the paw pressure test.
将胆囊收缩素（CCK 8）的C末端八肽鞘内注射给大鼠。纳克剂量在注射后五分钟的爪部压力试验中产生微弱但显著的抗伤害感受，而微克剂量的CCK 8则产生痛觉过敏。在甩尾试验中未观察到CCK 8诱导的镇痛或痛觉过敏，且与运动功能丧失或任何其他明显的副作用无关。发现CCK的C末端四肽（CCK 4）和五肽胃泌素在所有试验中均无效，但蛙皮素和软体动物心脏兴奋神经肽（FMRF酰胺）与CCK 8一样，在爪部压力试验中产生抗伤害感受。
